Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2000

View Archived Issues

Case studies reveal that gabapentin reduces the frequency of hot flashes

Pilot trial of IL-10 demonstrates improvement in liver histology in chronic HCV patients

(S)-Oxybutynin phase II trial successfully completed

FDA approves Apligraf for diabetic foot ulcers

Celgene and NCI to enter into cooperative R&D agreement for IMiDs

Novavax to begin phase I trial of Androsorb testosterone replacement therapy for women

Corvas completes enrollment for rNAPc2 phase II study

Extended-release venlafaxine proven safe and effective for the treatment of GAD

Applied Molecular Evolution creates anti-RSV monoclonal antibodies

Antibacterial efficacy results of Demegen peptide compound presented

Collaboration to develop CpG DNA-based cancer products

AVI BioPharma and DepoMed explore oral delivery of AVI's antisense agents

Taiwan researchers patent AT1 receptor antagonists with potential in cardiovascular conditions

PNU-190192 and related indolylpyrrolidinemethylpyrrole derivatives as immunosuppressants

Potent tricyclic protein farnesyltransferase inhibitors described by Schering-Plough

Structurally novel compounds synthesized at Leo exert potent insulinotropic activity

Peptide inhibitors of procollagen C-proteinase useful for fibrotic disorders

Agents for herpesvirus infections in development at Boehringer Ingelheim

Novel neuroprotective compounds exert NMDA-activating, AMPA-inhibiting effects

New phospholipase A2 inhibitors presented by Elan in patent literature

Triangle updates development status of clevudine

Japanese team designs new type of anti-HIV prodrug comprising a protease inhibitor and RT inhibitor

LM-1507.Na -- a potent and selective Cys-LT1 receptor antagonist with oral activity

Liposomal formulation of PGE1 prodrug shows promise in peripheral arterial occlusive disease

Nature article reports new anti-TB compound with unique properties

Marimastat does not meet primary or secondary endpoints in brain cancer trial

First clinical results reported for TS-943, a new small-molecule antiplatelet agent

Additive or synergistic effects of surfactant and PDE4 inhibitor in acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...